Clinical Effect of Azithromycin Combined with Simvastatin in Treating COPD Patients Merged with Pulmonary Arterial Hypertension: a Meta-analysis
Yu-ling ZHAO,Ya DONG,Ya-li FAN,Na-miao LI,Ying-ying ZHANG,Jun YU,Jian-ying LI
DOI: https://doi.org/10.3969/j.issn.1008-5971.2018.03.y01
2018-01-01
Abstract:Objective To evaluate the clinical effect of azithromycin combined with simvastatin in treating COPD patients merged with pulmonary arterial hypertension. Methods We searched PubMed, Medline, CNKI, VIP and WanFang Data to collect pertinent literatures about clinical effect of azithromycin combined with simvastatin in treating COPD patients merged with pulmonary arterial hypertension from creating database to March 2017. Patients in control group received simvastatin, while patients in test group received azithromycin combined with simvastatin; RevMan 5.3.0 software was used to carry out the Meta-analysis. Results A total of 9 literatures (all were Chinese) were involved at last, including 776 patients. Meta-analysis results showed that, FVC 〔MD=0.39, 95%CI (0.36, 0.41), P<0.000 01〕 and FEV1〔MD=0.35, 95%CI (0.23, 0.47), P<0.000 01〕 in test group were statistically significantly larger than those in control group after treatment, PaO2〔MD=8.32, 95%CI (7.37, 9.26), P<0.000 01〕 and SaO2〔MD=3.82, 95% CI (3.17, 4.48), P<0.000 01〕 in test group were statistically significantly higher than those in control group after treatment, pulmonary arterial systolic pressure 〔MD=-1.00, 95%CI (-1.30, -0.71), P<0.000 01〕, pulmonary artery dystolic pressure 〔MD=-1.37, 95%CI (-1.49, -1.25), P<0.000 01〕 and CRP 〔MD=-8.33, 95%CI (-9.91,-6.74), P<0.000 01〕in test group were statistically significantly lower than those in control group after treatment, while 6-minute walking distance in test group was statistically significantly longer than that in control group after treatment 〔MD=75.78, 95%CI (70.85, 80.72), P<0.000 01)〕. Conclusion Based on existing literature evidence, azithromycin combined with simvastatin can effectively improve the cardio-pulmonary function, adjust the arterial blood-gas analysis index, reduce the pulmonary arterial pressure and inflammatory reaction in treating COPD patients merged with pulmonary arterial hypertension.